{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:44:41Z","timestamp":1791927881461,"version":"4.3.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"DOI":"10.1007\/s00405-026-10708-9","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:46:18Z","timestamp":1791924378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Audiovestibular adverse event reporting profiles of GLP-1 receptor agonists: A case-case pharmacovigilance study using FDA AEMS data"],"prefix":"10.1007","author":[{"given":"Xianwen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyi","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1470-2256","authenticated-orcid":false,"given":"Hairui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"10708_CR1","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ (2018) Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 27:740\u2013756. https:\/\/doi.org\/10.1016\/j.cmet.2018.03.001","journal-title":"Cell Metab"},{"key":"10708_CR2","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/bph.15682","volume":"179","author":"A Kabahizi","year":"2022","unstructured":"Kabahizi A, Wallace B, Lieu L, Chau D, Dong Y, Hwang ES et al (2022) Glucagon-like peptide-1 signaling in the brain: from neural circuits and metabolism to therapeutics. Br J Pharmacol 179:600\u2013624. https:\/\/doi.org\/10.1111\/bph.15682","journal-title":"Br J Pharmacol"},{"key":"10708_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-149-1-200807010-00231","volume":"149","author":"KE Bainbridge","year":"2008","unstructured":"Bainbridge KE, Hoffman HJ, Cowie CC (2008) Diabetes and hearing impairment in the United States: audiometric evidence from the National Health and Nutrition Examination Survey, 1999\u20132004. Ann Intern Med 149:1\u201310. https:\/\/doi.org\/10.7326\/0003-4819-149-1-200807010-00231","journal-title":"Ann Intern Med"},{"key":"10708_CR4","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1097\/MAO.0b013e3181f2f035","volume":"31","author":"Y Agrawal","year":"2010","unstructured":"Agrawal Y, Carey JP, Della Santina CC, Schubert MC, Minor LB (2010) Diabetes, vestibular dysfunction, and falls: analyses from the National Health and Nutrition Examination Survey. Otol Neurotol 31:1445\u20131450. https:\/\/doi.org\/10.1097\/MAO.0b013e3181f2f035","journal-title":"Otol Neurotol"},{"key":"10708_CR5","doi-asserted-by":"publisher","first-page":"e281","DOI":"10.1055\/s-0041-1726041","volume":"26","author":"P Kumar","year":"2022","unstructured":"Kumar P, Singh NK, Apeksha K, Ghosh V, Kumar RR, Muthaiah BK (2022) Auditory and vestibular functioning in individuals with type-2 diabetes mellitus: a systematic review. Int Arch Otorhinolaryngol 26:e281\u2013e288. https:\/\/doi.org\/10.1055\/s-0041-1726041","journal-title":"Int Arch Otorhinolaryngol"},{"key":"10708_CR6","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1002\/lary.32061","volume":"135","author":"FI Khan","year":"2025","unstructured":"Khan FI, Vazquez SGS, Mehdi Z, Somawardana I, Dongre R, Razmi S et al (2025) Otolaryngologic side effects of GLP-1 receptor agonists. Laryngoscope 135:2291\u20132298. https:\/\/doi.org\/10.1002\/lary.32061","journal-title":"Laryngoscope"},{"key":"10708_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/MAO.0000000000004373","volume":"46","author":"KY Pak","year":"2025","unstructured":"Pak KY, Cutri RM, Nadeem W et al (2025) GLP-1 receptor agonist induced Eustachian tube dysfunction: database and systematic review of otolaryngologic adverse events. Otol Neurotol 46:19\u201322. https:\/\/doi.org\/10.1097\/MAO.0000000000004373","journal-title":"Otol Neurotol"},{"key":"10708_CR8","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3390\/biomedicines13051049","volume":"13","author":"EA Toraih","year":"2025","unstructured":"Toraih EA, Alenezy A, Hussein MH, Hashmat S, Mummadi S, Alrawili NF et al (2025) The risk of vestibular disorders with semaglutide and tirzepatide: findings from a large real-world cohort. Biomedicines 13:1049. https:\/\/doi.org\/10.3390\/biomedicines13051049","journal-title":"Biomedicines"},{"key":"10708_CR9","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.7150\/ijms.131397","volume":"23","author":"JY Huang","year":"2026","unstructured":"Huang JY, Lu YT, Hsin CH, Lo TS, Lee CY, Yang SF, Liao MY (2026) Risk of peripheral vestibular disorders and hearing impairment among users of glucagon-like peptide-1 receptor agonists. Int J Med Sci 23:1577\u20131587. https:\/\/doi.org\/10.7150\/ijms.131397","journal-title":"Int J Med Sci"},{"issue":"Suppl 3","key":"10708_CR10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/milmed\/usae142","volume":"189","author":"S Jiang","year":"2024","unstructured":"Jiang S, Cai M, Salvi R et al (2024) Therapeutic function of liraglutide for mitigation of blast-induced hearing damage. Mil Med 189(Suppl 3):407\u2013415. https:\/\/doi.org\/10.1093\/milmed\/usae142","journal-title":"Mil Med"},{"key":"10708_CR11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST (2004) The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13:519\u2013523. https:\/\/doi.org\/10.1002\/pds.1001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10708_CR12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJW (2009) Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 18:427\u2013436. https:\/\/doi.org\/10.1002\/pds.1742","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10708_CR13","unstructured":"US Food and Drug Administration (2026) FDA Adverse Event Monitoring System (AEMS): latest quarterly data files. https:\/\/www.fda.gov\/drugs\/fda-adverse-event-monitoring-system-aems\/fda-adverse-event-monitoring-system-aems-latest-quarterly-data-files. Accessed 13 July 2026"},{"key":"10708_CR14","unstructured":"US Food and Drug Administration (2026) FDA Adverse Event Monitoring System (AEMS) public dashboard. https:\/\/www.fda.gov\/drugs\/fda-adverse-event-monitoring-system-aems\/fda-adverse-event-monitoring-system-aems-public-dashboard. Accessed 13 July 2026"},{"key":"10708_CR15","unstructured":"US Food and Drug Administration (2025) BYETTA (exenatide) prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021773s050lbl.pdf. Accessed 29 Aug 2026"},{"key":"10708_CR16","unstructured":"US Food and Drug Administration (2025) SAXENDA (liraglutide) prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/206321s022lbl.pdf. Accessed 29 Aug 2026"},{"key":"10708_CR17","unstructured":"US Food and Drug Administration (2026) TRULICITY (dulaglutide) prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/125469s065lbl.pdf. Accessed 29 Aug 2026"},{"key":"10708_CR18","unstructured":"US Food and Drug Administration (2025) ADLYXIN (lixisenatide) prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/208471s010lbl.pdf. Accessed 29 Aug 2026"},{"key":"10708_CR19","unstructured":"US Food and Drug Administration (2025) WEGOVY (semaglutide) prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215256s024lbl.pdf. Accessed 29 Aug 2026"},{"key":"10708_CR20","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3390\/ph18050735","volume":"18","author":"JJ Chen","year":"2025","unstructured":"Chen JJ, Hsu CW, Hung CM, Liang CS, Su KP, Carvalho AF et al (2025) Risk of hearing loss in patients treated with exendin-4 derivatives: a network meta-analysis of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors. Pharmaceuticals (Basel) 18:735. https:\/\/doi.org\/10.3390\/ph18050735","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-026-10708-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-026-10708-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-026-10708-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:46:20Z","timestamp":1791924380000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-026-10708-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":20,"alternative-id":["10708"],"URL":"https:\/\/doi.org\/10.1007\/s00405-026-10708-9","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"14 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This study used deidentified, publicly available spontaneous-report data and involved no direct interaction with human participants.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}